Loading clinical trials...
Loading clinical trials...
Serial Cardiac Magnetic Resonance Imaging (CMR) With Contrast Agents and Biomarker Analysis for the Detection of Cardiotoxicity Under Anthracycline-containing Cancer Therapy - A Monocentric, Low Interventional Phase IV Pilot Study
Conditions
Interventions
CMR based measurement of cardiotoxicity
biosampling for scientific research in study-specific biobank
Locations
1
Germany
Robert Bosch Gesellschaft für Medizinische Forschung mbH
Stuttgart, Germany
Start Date
March 4, 2026
Primary Completion Date
August 1, 2029
Completion Date
March 1, 2030
Last Updated
April 14, 2026
NCT07191730
NCT07382141
NCT05023785
NCT05271162
NCT06132984
NCT06778122
Lead Sponsor
Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions